<DOC>
	<DOCNO>NCT01382212</DOCNO>
	<brief_summary>The objective evaluate safety paricalcitol capsule pediatric subject , age 10 16 year old , Stage 5 chronic kidney disease ( kidney failure ) receive peritoneal dialysis hemodialysis treat secondary hyperparathyroidism . Subjects dose period study 12 week order evaluate incidence hypercalcemia ( high calcium level blood ) . Approximately 12 subject enrol 12 receive paricalcitol capsule .</brief_summary>
	<brief_title>A Study Evaluate Safety Paricalcitol Capsules Pediatric Subjects Ages 10 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Subject must receive peritoneal dialysis hemodialysis least 3 month prior Screening Subject currently diagnose and/or treat secondary hyperparathyroidism For entry Dosing Period ( subject naïve Vitamin D Receptor [ VDR ] Activators complete 2 12 week washout ) , subject must meet follow laboratory criterion prior enrollment : A corrected calcium value ≥ 8.2 ≤ 10.4 mg/dL A phosphorus value ≤ 6.5 mg/dL An intact parathyroid hormone ( iPTH ) value &gt; 300 pg/mL less ≤ 2000 pg/mL Subject expect scheduled receive living donor kidney transplant within 3 month Screening kidney transplant patient require full immunosuppressant therapy Subject expect stop peritoneal dialysis hemodialysis within 4 month Screening ( per investigator discretion ) Subject parathyroidectomy within 12 week prior Screening Subject symptomatic significant hypocalcemia require VDR Activator therapy ( i.e. , calcitriol , paricalcitol , doxercalciferol ) within 2 month prior Screening Subject take maintenance calcitonin , bisphosphonates , glucocorticoid equivalent dose great 5 mg prednisone daily , drug know affect calcium bone metabolism within 4 8 week prior Dosing Subject receive cinacalcet time Screening</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Evaluate safety evaluation incidence hypercalcemia pediatric subject</keyword>
</DOC>